SCHEMBL3280433

SCHEMBL3280433

C[S+]([O-])c1cccc(CCl)c1

nearest known ligand 0.43

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.43
TTR P02766 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14330966 0.82 TP53 (0.41)
SCHEMBL21770501 0.80 TAAR1 (0.39) TSHR
SCHEMBL7050700 0.80
SCHEMBL7056116 0.80 CHRM2 (0.30)
SCHEMBL7056118 0.80 ENPP2 (0.42) TSHR
SCHEMBL5546072 0.80
SCHEMBL7050707 0.80 PNMT (0.45)
Hydrochloric Acid SCHEMBL1019605 0.78 PNMT (0.44)
SCHEMBL12586330 0.77 KDM4E (0.45)
SCHEMBL14983926 0.77 GABRA1 (0.38)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8569317-B2 Aryl-quinazoline/aryl-2amino-phenyl methanone derivatives NOVARTIS AG (CH) 2013-10-29 US disclosed
US-7696216-B2 Aryl-quinazoline/aryl-2-amino-phenyl methanone derivatives NOVARTIS AG (CH) 2010-04-13 US disclosed
US-20100063075-A1 Aryl-quinazoline/aryl-2amino-phenyl methanone derivatives ALTMANN EVA 2010-03-11 US disclosed
CN-101445486-A Derivatives of aryl-quinazoline/aryl-2-amino-phenyl methanone which promote the release of parathyroid hormone NOVARTIS PHARMA AG (CH) 2009-06-03 CN disclosed
EP-1585521-B8 DERIVATIVES OF ARYL-QUINAZOLINE/ARYL-2AMINO-PHENYL METHANONE WHICH PROMOTE THE RELEASE OF PARATHYROID HORMONE NOVARTIS AG (CH) 2009-03-25 EP disclosed
EP-1585521-B1 DERIVATIVES OF ARYL-QUINAZOLINE/ARYL-2AMINO-PHENYL METHANONE WHICH PROMOTE THE RELEASE OF PARATHYROID HORMONE NOVARTIS AG (CH) 2008-06-18 EP disclosed
EP-1844780-A2 Derivatives of aryl-quinazoline/aryl-2-amino-phenyl methanone which promote the release of parathyroid hormone Novartis Pharma AG (CH) 2007-10-17 EP disclosed
US-20060079685-A1 Aryl-quinazoline/aryl-2amino-phenyl methanone derivatives NOVARTIS AG (CH) 2006-04-13 US disclosed
CN-1732002-A Aryl-quinazoline/aryl-2-amino-phenyl methanone derivatives for promoting parathyroid hormone release NOVARTIS AG (CH) 2006-02-08 CN disclosed
EP-1585521-A2 DERIVATIVES OF ARYL-QUINAZOLINE/ARYL-2AMINO-PHENYL METHANONE WHICH PROMOTE THE RELEASE OF PARATHYROID HORMONE Novartis AG (CH) 2005-10-19 EP disclosed
WO-2004056365-A2 DERIVATIVES OF ARYL-QUINAZOLINE/ARYL-2AMINO-PHENYL METHANONE WHICH PROMOTE THE RELEASE OF PARATHYROID HORMONE NOVARTIS AG (CH) 2004-07-08 WO disclosed
EP-1112265-B1 2-ARYLALKYLTHIO -IMIDAZOLES, 2-ARYLALKENYL -THIO -IMIDAZOLES AND 2-ARYLALKINYL -THIO -IMIDAZOLES AS ANTI -INFLAMMATORY SUBSTANCES AND SUBSTANCES INHIBITING THE RELEASE OF CYTOKINE MERCKLE GMBH (DE) 2004-01-14 EP disclosed
US-6432988-B1 RHEUMATIC DISEASES, (OSTEO)ARTHRITIS, CACHEXIA, INFLAMMATORY BOWEL DISEASE, TOXIC SHOCK SYNDROME, SEPSIS, CROHN*S DISEASE, PSORIASIS AND GOUT TREATMENT MERCKLE GMBH (DE) 2002-08-13 US disclosed
EP-1112265-A1 2-ARYLALKYLTHIO -IMIDAZOLES, 2-ARYLALKENYL -THIO -IMIDAZOLES AND 2-ARYLALKINYL -THIO -IMIDAZOLES AS ANTI -INFLAMMATORY SUBSTANCES AND SUBSTANCES INHIBITING THE RELEASE OF CYTOKINE MERCKLE GMBH (DE) 2001-07-04 EP disclosed
WO-2000017192-A1 2-ARYLALKYLTHIO -IMIDAZOLES, 2-ARYLALKENYL -THIO -IMIDAZOLES AND 2-ARYLALKINYL -THIO -IMIDAZOLES AS ANTI -INFLAMMATORY SUBSTANCES AND SUBSTANCES INHIBITING THE RELEASE OF CYTOKINE MERCKLE GMBH (DE) 2000-03-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060079685-A1 Aryl-quinazoline/aryl-2amino-phenyl methanone derivatives PTH1R, PTMS, CYP24A1 TSHR 247/4885TTR 4392/4885
US-20100063075-A1 Aryl-quinazoline/aryl-2amino-phenyl methanone derivatives PTH1R, PTMS, CYP24A1 TSHR 252/4885TTR 4394/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.